Angiotensin-Converting Enzyme (ACE) D Allele as a Risk Factor for Increase Serum Interleukin-6 and Interleukin-8 in Psoriasis Patients

Ahmed I. Abd Elneam1,2, Mohammed Saleh Al-Dhubaibi3, Ali Ismaiel Ali Abd Alrheam4

1Molecular Genetics and Enzymology Department, Human Genetics Division, National Research Centre, 33 El Bohouth St. (former El Tahrir St.), Dokki 12622, Cairo, Egypt; 2Department of Clinical Biochemistry, Faculty of Medicine Al-dawdmi, Shaqra University, Saudi Arabia; 3Department of Dermatology, Faculty of Medicine Addawdmi, Shaqra University, Saudi Arabia; 4Department of Clinical Laboratory, Faculty of Applied Medical Science Al-dawdmi, Shaqra University, Saudi Arabia

Abstract

BACKGROUND: Psoriasis is a chronic, recurrent inflammatory skin disease. It is characterised by autoimmune, environmental factors and complex genetic disorder.

AIM: To explore the role of IL-6, IL-8, and ACE I/D polymorphism in the pathogenesis of Psoriasis and investigation of the relationship between ACE polymorphism and occurrence of psoriasis.

PATIENTS AND METHODS: In this study, we took 73 psoriasis patients and 47 healthy patients as a control. These two groups subjected to analysis for patients compared to healthy subjects (P < 0.001). ID and DD polymorphism were more common in psoriasis patients than healthy subjects. Also, D allele was significantly over-represented in patients compared to controls (52.7% Vs 35.1%).

CONCLUSION: ACE gene polymorphism might grant susceptibility to develop psoriasis.

Introduction

Psoriasis is a chronic, recurrent inflammatory skin disease that can have a great effect on a patient’s self-esteem [1]. It is affected by autoimmune, environmental factors and complex genetic disorder [2]. The effect of the disease is not only limited solely to the skin but also causes permanent joint damage in nearly 30% of the patients [3].

Angiotensin-converting enzyme (ACE) is a zinc metallopeptidase, located on chromosome 17q23. It contains an insertion (I)/deletion (D) polymorphism within intron 16 that contain the most genetic variables of the variability of serum ACE activity and is associated with the development of psoriasis [4].

Several studies indicated that Angiotensin-converting enzyme is a major and effective factor in creating angiotensin II (Ang II) and inactivating bradykinin [5] [6].

Active angiotensin II increases the production of reactive oxygen species (ROS) and the synthesis of cytokines such as interleukin-6 (IL-6) and IL-8 which play an important role in the development of psoriasis [7]. Also, inactivation of bradykinin by ACE stimulates...
the synthesis of cytokines such as IL-6, IL-8 and nitric oxide (NO) [8] [9] [10].

Interleukin 6 (IL-6) is a major inducer of regulated expression of many cytokines [11]. IL-6 is one of the normal skin components, and it was immunologically founded in endothelial cells, keratinocytes, and fibroblasts [11]. IL-6 has been suggested to function as an autocrine mitogen in the psoriatic epidermis [12].

Interleukin 8 (IL-8) is one of the most common chemokines that is elevated in the psoriatic lesion [13]. Moreover, both mRNA and peptide IL-8 have been detected in situ in psoriatic patients [14]. Elevated IL-8 blood levels are considered as a marker for the systemic inflammatory disorders [15].

Our main goal was to explore the role of IL-6, IL-8, and ACE I/D polymorphism in the pathogenesis of Psoriasis. Also, our specific aim is to investigate the relationship between ACE polymorphism and occurrence of psoriasis.

Subject and Methods

The present study was performed at Outpatient Dermatology Clinic, Buraidah Central Hospital, Qassim region, Saudi Arabia between October 2016 and May 2017.

A total of 73 patients (42 male and 31 females) were enrolled for this case-control study. The diagnosis was established by clinically-physical examination as the diagnosis was striated forward (All patients had characteristic erythematous plaques located on the trunk and limbs). Patients had an only cutaneous form of psoriasis, with no systemic involvements were included in the study. None of the patients had received any systemic immunosuppressive medications or used any local treatment at the site of biopsies for 4 weeks before study participation.

Patients were classified according to body surface area (BSA) into severe psoriasis vulgaris greater than 10% of the body surface, moderate psoriasis vulgaris 5%-10% of the body surface and mild psoriasis vulgaris less than 5% of the body surface [16].

The other 47 subjects were healthy volunteers who were age and gender-matched with the psoriasis group (27 male and 20 females), they had no clinical evidence or family history of psoriasis or any other autoimmune disorder.

Both groups had undergone complete physical and clinical examinations, genetics studies and biochemical tests.

Before the initiation of the study, informed consent was obtained from all individuals chosen for the study. The aim and the value of the work were explained to them in a simplified manner. This study was approved by the Local Medical Ethical Committee and according to their instructions.

Serum ACE concentrations were measured, utilising the Human ACE Quantikine ELISA Kit from R&D Biotech brand system [17].

The interleukin-6 level was determined using a commercially available ELISA kit (Quantikine, human IL-6R & D Systems, Minneapolis, USA) by the manufacturer's instructions [18].

Serum samples from all patients were tested in a sandwich ELISA using according to the manufacturers' instructions (R&D, Minneapolis, USA; Bender, Vienna; Amersham, Germany) [19].

Blood samples were collected on Na2EDTA as an anticoagulant. Genomic DNA was purified from 200 μl whole blood with the QIAamp® DNA BloodMini Kit according to manufacture instruction for Blood protocol.

To determine the ACE gene I/D polymorphism, a genomic DNA fragment on intron 16 of the ACE gene was amplified by using Polymerase Chain Reaction (PCR) method with a pair of oligonucleotide primers: The upstream of primer sequence was: 5'-CTG GAG ACC ACT CCC ATC CTT TCT -3' and the downstream was: 5'- GAT GTG GCC ATC ACA TTC GTC AGA T -3' (20). The primers were blasted to the gene bank database https://blast.ncbi.nlm.nih.gov/Blast.cgi [21].

Data was presented by means ± SD and percentages. The compiled data were computerised and analysed by SPSS PC+, version 12. The following tests of significance were used: Analysis of variance (ANOVA) test between more than two means, t-test between means we used to analyse the mean difference, t-test between percentage to analyse percent difference and chi-square. A level of significance with p ≤ 0.001 was considered highly significant and p > 0.05 was considered insignificant.

Results

In our present study, we analysed ACE gene polymorphism for Seventy-three (42 male and 31 females) psoriasis patients and Forty-seven (27 male and 20 females) healthy controls they had no clinical evidence or family history of psoriasis or of any other autoimmune disorder. Clinical and General Data of all the patients and controls are shown in Table 1. It was noted that serum ACE, serum IL-8 and serum IL-6
were statistically significantly higher in psoriasis patients than in healthy subjects (P < 0.001).

Clinical presentation of psoriasis showed that 23 patients (31.5%) have severe psoriasis vulgaris, 26 patients (33.5%) have moderate psoriasis vulgaris and 24 patients (33%) have mild psoriasis.

Table 1: General and laboratory characteristics of psoriatic patients and healthy control

| Parameters                  | Patients (N = 73) | Control (N = 47) | P-value |
|-----------------------------|------------------|-----------------|---------|
| Age (years; Mean ± SD)      | 41.2 ± 4.9       | 38.1 ± 6.8      | 0.411   |
| Male-Female (N, %)          | 42(52.7%)/31(47.3%) | 27(57.4%)/20(42.6%) | 0.442   |
| Severe psoriasis vulgaris (N, %) | 23 (31.5)       |                 |         |
| Moderate psoriasis vulgaris (N, %) | 28 (33.5)       |                 |         |
| Mild psoriasis vulgaris (N, %) | 24 (33%)         |                 |         |
| Presence of Family history (N, %) | 46 (63%)        |                 |         |
| Absent of Family history (N, %) | 27 (37%)        |                 |         |
| Serum ACE (IU/L)            | 8.9 ± 0.60      | 7.6 ± 1.5       | <0.001* |
| Serum IL-6 (pg/ml)          | 17.5 ± 0.48     | 8.9 ± 0.60      | <0.001* |
| Serum IL-8 (pg/ml)          | 15.9 ± 0.9      | 7.6 ± 1.5       | <0.001* |

SD, standard deviation; ACE, angiotensin-converting enzyme; IL-6, interleukin-6; IL-8, interleukin-8; N, Number; * Significance between healthy Subjects and psoriatic patients (P < 0.05).

Comparison of ACE genotypes in patients and controls showed that I/D were the most common (45.2%) followed by D/D (30.1%) then I/I (24.7%). I/I was the most common in severe patients (46.8%) while I/D and D/D genotypes were found to be 36.2% and 17% respectively (Table 2).

Table 2: Comparison of ACE genotype in psoriatic patients and healthy control

| Genotypes | Patients (N, %) | Control (N, %) | P-Value |
|-----------|----------------|---------------|---------|
| I/I       | 18 (24.7%)     | 22 (46.8%)    | 0.001*  |
| I/D       | 33 (45.2%)     | 17 (36.2%)    | 0.872   |
| D/D       | 22 (30.1%)     | 8 (17%)       | 0.001*  |

N, number; * p-value<0.05 is statistically significant.

The allele frequency was significantly different between patients and controls (P = 0.005). The results indicated that the D allele was significantly over-represented in patients compared to the controls (52.7% vs 35.1%) (Table 3).

Table 3: Comparison of allele frequency in psoriatic patients and healthy control

| Alleles frequency | Patients (N, %) | Control (N, %) | P-Value |
|-------------------|----------------|---------------|---------|
| I                 | 69 (47.3%)     | 61 (43.9%)    | 0.002   |
| D                 | 77 (52.7%)     | 33 (35.1%)    |         |

N, number; * p-value<0.05 is statistically significant.

Patients with DD genotypes have statistically significantly higher levels of serum ACE (P < 0.001), higher serum IL-8 (P < 0.001) and higher serum IL-6 (P < 0.001), Table 4.

Table 4: Comparison of biochemical parameters and ACE genotypes in psoriatic patients

| Parameters                  | Patients (n = 33) | Control (n = 22) | P-value |
|-----------------------------|------------------|-----------------|---------|
| Serum ACE (IU/L)            | 16.88 ± 4.52     | 23.66 ± 1.66    | 0.001   |
| Serum IL-6 (pg/ml)          | 23.67 ± 3.9      | 29.24 ± 1.54    | 0.001   |
| Serum IL-8 (pg/ml)          | 12.66 ± 2.3      | 18.34 ± 1.6     | 0.001   |

SD, standard deviation; ACE, angiotensin-converting enzyme; IL-6, interleukin-6; IL-8 interleukin-8; N, Number; * Significance between healthy Subjects and psoriatic patients (P < 0.05).

Comparison of biochemical parameters and variable clinical types of psoriasis indicated that the levels of serum ACE, serum IL-6, and IL-8 higher in Severe psoriasis vulgaris patients than in those with Moderate psoriasis and Mild psoriasis vulgaris with P-values 0.012, 0.001 and 0.008 respectively (Table 5).

Table 5: Comparison of biochemical parameters and variable clinical types of psoriasis in our patients

| Parameters                  | Severe psoriasis vulgaris (N = 23) | Moderate psoriasis vulgaris (N = 26) | Mild psoriasis vulgaris (N = 24) | P-value |
|-----------------------------|------------------------------------|-------------------------------------|---------------------------------|---------|
| Serum ACE (IU/L)            | 22.25 ± 1.21                      | 18.9 ± 2.88                        | 14.79 ± 2.7                    | 0.012   |
| Serum IL-6 (pg/ml)          | 38.5 ± 4.5                        | 21.56 ± 3.9                       | 17.44 ± 2.55                   | 0.001*  |
| Serum IL-8 (pg/ml)          | 22.3 ± 3.8                        | 14.99 ± 2.88                      | 11.23 ± 1.3                    | 0.008*  |

Our results showed that D/D genotype was more common with severe psoriasis vulgaris (52.2%). On the other side, I/D was more frequent in Moderate psoriasis vulgaris and Mild psoriasis vulgaris patients (50% and 58.3% respectively) (Table 6).

Table 6: Comparison of ACE genotypes and variable clinical types of psoriasis in our patients

| Parameters                  | I/I (N, %) | I/D (N, %) | D/D (N, %) | P-value |
|-----------------------------|-----------|-----------|-----------|---------|
| Severe psoriasis vulgaris    | 5 (21.7%) | 6 (26.1%) | 12 (52.2%)| 0.001*  |
| Moderate psoriasis vulgaris  | 6 (23.1%) | 13 (50%)  | 7 (26.9%) | 0.001*  |
| Mild psoriasis vulgaris      | 7 (29.1%) | 14 (58.3%)| 3 (12.6%) | 0.001*  |

*Significance between healthy Subjects and psoriatic patients (P < 0.05).

Discussion

The present study provides a relationship between ACE I/D polymorphism, IL-6, IL-8 and psoriasis as a risk factor was determined.

Our results indicated that psoriasis patients have serum IL-6 and serum IL-8 were significantly higher than in controls (P < 0.001). Our results are in line with several studies [22] [23] [24] they reported that elevated levels of serum IL-6 and serum IL-8 in psoriasis vulgaris patients.

The results of the current study indicated that the ACE polymorphism of the I/I genotype was more frequent in controls (46.8%) than in psoriasis patients (24.7%), while the I/D and the D/D genotypes were more abundant in psoriasis vulgaris patients (45.2% and 30.1% respectively). However, this difference was statistically not highly significant, and this can be explained by the small sample size of our study. Also, we observed that DD genotype was more common in patients with severe psoriasis vulgaris (52.2%) than those with intermediate (26.9%) and mild (12.6%) disease. These results are consistent with Song et al., 2015 who revealed that frequency of DD and ID in case more than II [25].

Our results revealed that D allele was significantly higher in the psoriasis patients (52.7%) than in controls (35.1%). These results were consistent with Min Huang et al., 2017. Who found that the D allele was frequency higher in psoriasis.
patients than in the controls (43.8% and 31.8% respectively) [26].

Multiple studies have been performed to detect the polymorphisms as an important factor in the development of psoriasis: TNF α gene -238G/A polymorphism [27] -2518 A/G MCP-1 and -403 G/A RANTES promoter gene polymorphisms [28], CARD14 rs11652075 polymorphism [29] and support the genetic hypothesis in psoriasis.

Our findings showed that a significant relationship between the serum ACE levels in patients and healthy subjects (P < 0.001). Moreover, we showed a significant difference of the serum ACE levels with the different ACE genotypes; psoriasis patients with ACE DD genotype showed the highest mean ACE serum level (28.07 ± 3.21), while patients with ACE II genotype had the lowest mean serum ACE level (16.88 ± 4.22). In the present study, we observed that DD was associated with increased levels of IL-6 and IL-8 (47.22 ± 2.5 and 28.32 ± 4.1 respectively). Also, comparison of biochemical parameters and variable clinical types of psoriasis in our patients showed increased levels of all variables in patients with severe psoriasis vulgaris compared to those with Moderate psoriasis vulgaris and mild psoriasis vulgaris.

Increased levels of serum ACE, IL-6 and IL-8 in psoriasis patients were due to the important role of ACE in inflammation. Where ACE converts Ang I into Ang II and inactivates bradykinin [30]. Ang II activates cytokines like IL-6 and IL-8, thus exerting proinflammatory effects [6]. This indicates an important role of ACE in the pathogenesis of psoriasis [31].

In conclusion, ACE gene polymorphism might confer susceptibility to the development psoriasis.

Acknowledgements

The authors are very grateful to Shaqra University, Ministry of Higher Education, Kingdom of Saudi Arabia for laboratory facility to do this research. We are also very much thankful to the Department of Clinical Biochemistry and Dermatology Department, Faculty of Medicine Al-Dawadmi, Shaqra University and Department of Clinical Biochemistry Laboratory Faculty of applied medical science Al-Dawadmi, Shaqra University Kingdom of Saudi Arabia for their help with laboratory facility. We may not proceed to this present work if they do not allow us. We again thank their ethical committee for approving.

References

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370:263-71. https://doi.org/10.1016/S0140-6736(07)61128-3

2. Mee JB, Johnson CM, Morar N, Burslem F, Groves RW. The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis. Am J Pathol. 2007; 171(1): 32-42. https://doi.org/10.1016/j.ajpath.2007.06.016 PMid:17591951 PMCid:PMC194577

3. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol. 2003; 4(7):441-7. https://doi.org/10.2165/00128071-200304070-00001 PMid:12814334

4. Rigat B1, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 96(4): 1343–6. https://doi.org/10.1172/JCI114844 PMid:1795655

5. Jia SY, Park HH, Li GZ, Lee HJ, Hong MS, Hong SJ, et al. Association of Angiotensin Converting Enzyme Gene I/D Polymorphism of Vitiligo in Korean Population. Pigment Cell Res. 2004; 17(1): 84–6. https://doi.org/10.1046/j.1600-0749.2003.00105.x PMid:14717849

6. Schothen TE, Ständer S, Riemann H, Brzoska T, Luger TA. Modulation of cutaneous inflammation by the angiotensin-converting enzyme. J Immunol. 2003; 170(7):3866–73. https://doi.org/10.4049/jimmunol.170.7.3866 PMid:12646655

7. Takahashi T, Taniguchi T, Okuda M, Takahashi A, Kawasaki S, Domoto K, et al. Participation of reactive oxygen intermediates in the angiotensin II-activated signalling pathways in vascular smooth muscle cells. Ann NY Acad Sci. 2000; 902: 283–7. https://doi.org/10.1111/j.1749-6632.2000.tb08323.x PMid:10865848

8. Beazley WD, Gaze D, Parske A, Panzic E, Schalleuter KU. Serum selenium levels and blood glutathione peroxidase activities in vitiligo. Br J Dermatol. 1999; 141(2):301–3. https://doi.org/10.1046/j.1365-2133.1999.02980.x PMid:10468804

9. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004; 113(12):1664–75. https://doi.org/10.1172/JCI20042147

10. Yildirim M, Baysal V, Inaloz HS, Can M. The role of oxidants and antioxidants in generalized vitiligo at tissue level. J Eur Acad Dermatol Venereol. 2004; 18(6):683–6. https://doi.org/10.1111/j.1468-3083.2004.01080.x PMid:15482295

11. Borden EC, Chin P. Interleukin-6: a cytokine with potential diagnostic and the therapeutic roles. J Lab Clin Med. 1994; 123(6):824-9. PMid:8201259

12. Castells-Rodellas A, Castell JV, Ramirez-Bosca A, Nicolas JF, Valcuende-Cavero F, Thivolet J. Interleukin-6 in normal skin and psoriasis. Acta Derm Venereol. 1992; 72(3):165–8. PMid:1357848

13. Gearing AJ, Fincham NJ, Bird CR, Wadhwa M, Meager A, Cartwright JE et al. Cytokines in skin lesions of psoriasis. Cytokine. 1990; 2(1):68–75. https://doi.org/10.1016/0952-8982(90)90045-U

14. Antilla HSI, Reitamo S, Erikko P, Ceska M, Moser B, Baggioni M. Interleukin-8 immunoreactivity in the skin of healthy subjects and patients with palmoplantar pustulosis and psoriasis. J Invest Dermatol. 1992; 98(1):96-101. https://doi.org/10.1111/1523-1747.ep12495817

15. Baggioni M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol. 1997; 15: 675-705. https://doi.org/10.1146/annurev.immunol.15.1.675 PMid:9143704

16. Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol. 1991; 124: 565-70.
17. Wang P, Holst C, Wodzig W, Andersen M, Astrup A, van Baak M et al. Circulating ACE is a predictor of weight loss maintenance not only in overweight and obese women, but also in men. Int J Obes (Lond). 2012; 36(12):1545-51. https://doi.org/10.1038/ijo.2011.278 PMid:22270380

18. März P, Cheng JG, Gadient RA, Patterson PH, Stoyan T, Otten U, et al. Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci USA. 1998; 95(6): 3251–6. https://doi.org/10.1073/pnas.95.6.3251 PMid:9501249 PMCID:PMC19728

19. Sticherling M, Hetzel F, Schroder J-M, Christophers E. Time- and stimulus-dependent secretion of NAP-1/IL-8 by human fibroblasts and endothelial cells. J Invest Dermatol. 1993; 101(4): 573-6. https://doi.org/10.1111/1523-1747.ep12366023

20. Dehwah MA, Shunag Z, Huang Q Y. The Association Between ACE Gene I/D Polymorphism and Type 2 Diabetes in Han Chinese in Hubei. Int J Osteop Meta Disor. 2008; 1(1):1-7.

21. Kapp A, Piskorski A, Schoep E. Elevated levels of interleukin 2 receptor in sera of patients with atopic dermatitis and psoriasis. British Journal of Dermatology. 1988; 119(6):707–710. https://doi.org/10.1111/j.1365-2133.1988.tb03491.x PMid:3264510

22. Abanmi A, Piskorski A, Schoep E. Elevated levels of interleukin 2 receptor in sera of patients with atopic dermatitis and psoriasis. British Journal of Dermatology. 1988; 119(6):707–710. https://doi.org/10.1111/j.1365-2133.1988.tb03491.x PMid:3264510

23. Abanmi A, Al Harthi F, Al Agla R, Khan HA, Tariq M. Serum levels of proinflammatory cytokines in psoriasis patients from Saudi Arabia. Int J Dermatol. 2005; 44(1):82–83. https://doi.org/10.1111/j.1365-4632.2004.02082.x PMid:15663670

24. Zalewksa A, Glowacka E, Wyczółkowska J, Tchorzewski H, Narbut J, Sysa-Jedrzejewska A. Interleukin 6 and 8 levels in plasma and fibroblast cultures in psoriasis. Mediators Inflamm. 2006; 2006(1):81767. https://doi.org/10.1155/MI/2006/81767

25. Song GG, Bae SC, Kim JH, Lee YH. The angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to rheumatoid arthritis, vitiligo and psoriasis: A meta-analysis. J Renin Angiotensin Aldosterone Syst. 2015; 16(1):195-202. https://doi.org/10.1177/1470320314537285 PMid:2413281

26. Min Huang, Guo-Dong Huang, Dan Peng. Angiotensin-converting enzyme I/D polymorphism and susceptibility of psoriasis. Biomedical Research. 2017; 28(12):5450-3.

27. Rajesh D, Gurumurthy R, Kutty AV, Balakrishna S. Tumor necrosis factor-alpha gene promoter -238G/A polymorphism increases the risk of psoriasis vulgaris in Indian patients. Int J Dermatol. 2017; 56:307-311. https://doi.org/10.1111/ijd.13482 PMid:28093730

28. Zablotna M, Sobijanek M, Purzycka-Bohdan D, Szczerkowska-Dobosz A, Nedoszytko B, Nowicki R. The -2518 A/G MCP-1 and -403 G/A RANTES promoter gene polymorphisms are associated with psoriasis vulgaris. Clin Exp Dermatol. 2016; 41(8): 878-83. https://doi.org/10.1111/ced.12937 PMid:27859608

29. Shi G, Li SJ, Wang TT, Cheng CM, Fan YM, Zhu KJ. The common CARD14 gene missense polymorphism rs11652075 (c.C2458T/ p.Arg820Trp) is associated with psoriasis: a meta-analysis. Genet Mol Res. 2016; 15(3). https://doi.org/10.4238/gmr.15038357

30. Ehlers MR, Riordan JF. Angiotensin-converting enzyme: new concepts concerning its biological role. Biochemistry. 1989; 28(13):5311–8. https://doi.org/10.1021/bi00439a001

31. Schremmer-Danninger E, Hermann A, Fink E, Fritz H, Roscher AA. Identification and occurrence of mRNAs for components of the kallikrein-kinin system in human skin and in skin diseases. Immunopharmacology.1999; 43(2-3):287–91. https://doi.org/10.1016/S0162-3109(99)00100-9